Galera

$10.15
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.15 (+1.50%) Today

$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Galera and other stocks, options, and ETFs commission-free!

About GRTX

Galera Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on developing and commercializing a pipeline of novel, proprietary therapeutics for cancer. The firm involves in the prevention of radiation-induced toxicity, including mucositis and the treatment of fibrosis and cancer. Its product candidate, GC4419, reduces severe oral mucositis in patients with head and neck cancer undergoing radiation therapy and also receiving cisplatin, a chemotherapy drug. The company was founded by Robert A. Beardsley, Randy W. Weiss, and Dennis P. Riley in 2009 and is headquartered in Malvern, PA. The listed name for GRTX is Galera Therapeutics, Inc. Common Stock.

CEO

J. Mel Sorensen

Employees

Headquarters

Malvern, Pennsylvania

Founded

2009

Market Cap

254.02M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

55.04K

High Today

$10.34

Low Today

$9.95

Open Price

$10.05

Volume

629.90K

52 Week High

$18.57

52 Week Low

$5.58

Collections

GRTX Earnings

-$51.43

-$34.29

-$17.14

$0.00

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 9, Pre-Market